GENMOR Platform
Uncovering Genetic Resilience to Accelerate Drug Discovery
How We Identify Human-Based Resistance to Disease
At Halia Therapeutics, the GENMOR Platform (Genetic Modifier of Resilience) is our proprietary discovery engine, designed to uncover why some individuals remain healthy despite having high-risk genetic mutations. By comparing these resilient individuals to those who develop disease, GENMOR identifies protective genetic modifiers and biological mechanisms that can be leveraged to create powerful, precision-targeted therapies.
This genetic resilience discovery platform represents a significant advancement in drug development, shifting the focus from treating illness to maintaining health.
What Is GENMOR?
A multi-layered approach that allows Halia to identify genetic modifiers of disease, helping us find human-proven targets for drug development. These discoveries are grounded in real-world clinical outcomes, not just in theory, but in the lived biology of patients.
GENMOR is a next-generation platform that integrates:
Genomic analysis
Family pedigree mapping
Linked electronic health records
AI-powered variant detection
Biological validation tools
Why GENMOR Is Different
Most drug discovery models begin with a disease. GENMOR begins with health, specifically with individuals who remain healthy despite carrying genes that typically increase disease risk.
This paradigm-shifting platform enables us to:
Compare genetically similar individuals with different health outcomes
Isolate protective genetic variants (e.g., those that neutralize APOE4, BRCA1/2, FTO)
Identify resilience pathways that operate across various diseases, including inflammation, metabolism, and immune regulation.
Because our targets are identified in people who are already resilient, we reduce the risk of failure in clinical trials and increase the likelihood of developing safe and effective medicines.
GENMOR Accelerates Precision Medicine
Our platform helps us move from discovery to therapy more efficiently by identifying
High-confidence drug targets rooted in human protection
Shared resilience mechanisms relevant across Alzheimer’s, cancer, cardiovascular, metabolic, and autoimmune diseases
Opportunities to intercept disease before it manifests
This makes GENMOR a precision medicine engine that doesn’t just find what’s broken — it finds what’s working and replicates it in the form of resilience-based therapeutics.
How GENMOR Powers Halia’s Pipeline
GENMOR-AI is the foundation of Halia’s drug pipeline.
HT-4253: Inspired by RAB10 modulation in APOE4 carriers, targeting Alzheimer’s
HT-6184: Targets LRRK2 and NEK7 to modulate inflammasome activity in metabolic and inflammatory diseases
Discovery-stage assets in dermatology, neuroinflammation, obesity, and autoimmunity
Each program began with a GENMOR-identified modifier that protects real people in real-life genetic studies.
A Future Built on Human Resilience
By tapping into population-scale health data, leveraging AI analytics, and focusing on resilient individuals, GENMOR enables Halia Therapeutics to pursue safer and smarter drug development. Our mission is to decode the biology of protection and turn that into medicine for everyone. GENMOR doesn’t just ask what causes disease. It asks what prevents it, and uses the answer to build the future of precision medicine.